Is Palisade Bio Stock a Good Investment?
Palisade Bio Investment Advice | PALI |
- Examine Palisade Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Palisade Bio's leadership team and their track record. Good management can help Palisade Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Palisade Bio's business and its evolving consumer preferences.
- Compare Palisade Bio's performance and market position to its competitors. Analyze how Palisade Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Palisade Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Palisade Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Palisade Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Palisade Bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Palisade Bio Stock
Researching Palisade Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.36. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Palisade Bio recorded a loss per share of 13.26. The entity last dividend was issued on the 18th of July 2019. The firm had 1:15 split on the 8th of April 2024.
To determine if Palisade Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Palisade Bio's research are outlined below:
| Palisade Bio generated a negative expected return over the last 90 days | |
| Palisade Bio has high historical volatility and very poor performance | |
| Palisade Bio has some characteristics of a very speculative penny stock | |
| Palisade Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 250 K. Net Loss for the year was (12.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palisade Bio currently holds about 5 M in cash with (11.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23. | |
| Palisade Bio has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Csimma Cristina of 6980 shares of Palisade Bio subject to Rule 16b-3 |
Palisade Bio Quarterly Accounts Payable |
|
Palisade Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Palisade Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Palisade Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Palisade Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Palisade Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -0.39 | -0.44 | -0.05 | 12 | ||
2023-08-11 | 2023-06-30 | -0.45 | -0.53 | -0.08 | 17 | ||
2023-05-11 | 2023-03-31 | -0.72 | -0.54 | 0.18 | 25 | ||
2024-08-09 | 2024-06-30 | -2.93 | -3.32 | -0.39 | 13 | ||
2024-11-07 | 2024-09-30 | -3.35 | -2.324 | 1.026 | 30 | ||
2024-03-26 | 2023-12-31 | -5.17 | -6.45 | -1.28 | 24 | ||
2013-05-10 | 2013-03-31 | -11.7 | -10.4 | 1.3 | 11 | ||
2022-08-15 | 2022-06-30 | -8.5 | -6.0 | 2.5 | 29 |
Know Palisade Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Palisade Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Palisade Bio backward and forwards among themselves. Palisade Bio's institutional investor refers to the entity that pools money to purchase Palisade Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 105.4 K | Cetera Investment Advisers | 2024-12-31 | 70 K | Geode Capital Management, Llc | 2024-12-31 | 10.1 K | Ubs Group Ag | 2024-12-31 | 9 K | Tower Research Capital Llc | 2024-12-31 | 4.7 K | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 100.0 | Wells Fargo & Co | 2024-12-31 | 21.0 | Bank Of America Corp | 2024-12-31 | 10.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 |
Palisade Bio's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.4 M.Market Cap |
|
Palisade Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (1.03) | (1.08) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (1.25) | (1.31) |
Determining Palisade Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Palisade Bio is a good buy. For example, gross profit margin measures Palisade Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Palisade Bio's profitability and make more informed investment decisions.
Evaluate Palisade Bio's management efficiency
Palisade Bio has return on total asset (ROA) of (0.682) % which means that it has lost $0.682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3596) %, meaning that it created substantial loss on money invested by shareholders. Palisade Bio's management efficiency ratios could be used to measure how well Palisade Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.83. The current Return On Capital Employed is estimated to decrease to -1.08. As of now, Palisade Bio's Fixed Asset Turnover is decreasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 22.33 | 23.44 | |
| Tangible Book Value Per Share | 22.33 | 23.44 | |
| Enterprise Value Over EBITDA | 0.59 | 0.62 | |
| Price Book Value Ratio | 0.41 | 0.39 | |
| Enterprise Value Multiple | 0.59 | 0.62 | |
| Price Fair Value | 0.41 | 0.39 | |
| Enterprise Value | -9.2 M | -8.8 M |
The decision-making processes within Palisade Bio are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.41 |
Basic technical analysis of Palisade Stock
As of the 21st of March, Palisade Bio holds the Variance of 115.82, risk adjusted performance of (0.02), and Coefficient Of Variation of (3,030). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Palisade Bio, as well as the relationship between them.Palisade Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Palisade Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Palisade Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Palisade Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Palisade Bio's Outstanding Corporate Bonds
Palisade Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Palisade Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Palisade bonds can be classified according to their maturity, which is the date when Palisade Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Palisade Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Palisade Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (1.38) | |||
| Mean Deviation | 5.69 | |||
| Coefficient Of Variation | (3,030) | |||
| Standard Deviation | 10.76 | |||
| Variance | 115.82 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | 0.5434 | |||
| Treynor Ratio | (1.39) | |||
| Maximum Drawdown | 93.57 | |||
| Value At Risk | (11.84) | |||
| Potential Upside | 12.73 | |||
| Skewness | 3.99 | |||
| Kurtosis | 26.06 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (1.38) | |||
| Mean Deviation | 5.69 | |||
| Coefficient Of Variation | (3,030) | |||
| Standard Deviation | 10.76 | |||
| Variance | 115.82 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | 0.5434 | |||
| Treynor Ratio | (1.39) | |||
| Maximum Drawdown | 93.57 | |||
| Value At Risk | (11.84) | |||
| Potential Upside | 12.73 | |||
| Skewness | 3.99 | |||
| Kurtosis | 26.06 |
Consider Palisade Bio's intraday indicators
Palisade Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Palisade Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.78 | |||
| Day Typical Price | 0.78 | |||
| Price Action Indicator | 0.0045 | |||
| Period Momentum Indicator | 0.003 |
Palisade Stock media impact
Far too much social signal, news, headlines, and media speculation about Palisade Bio that are available to investors today. That information is available publicly through Palisade media outlets and privately through word of mouth or via Palisade internal channels. However, regardless of the origin, that massive amount of Palisade data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Palisade Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Palisade Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Palisade Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Palisade Bio alpha.
Palisade Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Palisade Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Palisade Bio Corporate Management
| Joerg Heyer | Head Medicine | Profile | |
| Ryker Willie | Senior Controller | Profile | |
| Sharon McBrayer | Director Operations | Profile | |
| Mitchell MD | Chief Officer | Profile | |
| Robert McRae | VP Devel | Profile | |
| MD FAAAAI | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Palisade Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.